Jose A Santiago

Dr. Jose A Santiago

Cellular and Molecular Pharmacology, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
JSJose A Santiago
Jose A Santiago
JPJudith Potashkin
Judith Potashkin
A wide range of comorbid diseases is associated with Alzheimer's disease (AD), the most common neurodegenerative disease worldwide. Evidence from clinical and molecular studies suggest that chronic diseases, including diabetes, cardiovascular disease, depression, and inflammatory bowel disease, may be associated with an increased risk of AD in different populations. Disruption in several shared biological pathways has been proposed as the underlying mechanism for the association between AD and these comorbidities. Notably, inflammation is a common dysregulated pathway shared by most of the comorbidities associated with AD. Some drugs commonly prescribed to patients with diabetes and cardiovascular disease have shown promising results in AD patients. Systems-based biology studies have identified common genetic factors and dysregulated pathways that may explain the relationship of comorbid disorders in AD. Nonetheless, the precise mechanisms for the occurrence of disease comorbidities in AD are not entirely understood. Here, we discuss the impact of the most common comorbidities in the clinical management of AD patients.

1 March 2013 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
JSJose A Santiago
Jose A Santiago
JPJudith A. Potashkin
Judith A. Potashkin

7 March 2014 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
SSStacey E. Seidl
Stacey E. Seidl
JSJose A Santiago
Jose A Santiago
HBHope Therese Bilyk
Hope Therese Bilyk
JPJudith Potashkin
Judith Potashkin
Typically, Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease in ageing individuals. It is now clear that genetic susceptibility and environmental factors play a role in disease etiology and progression. Because environmental factors are involved with the majority of the cases of PD, it is important to understand the role nutrition plays in both neuroprotection and neurodegeneration. Recent epidemiological studies have revealed the promise of some nutrients in reducing the risk of PD since their intake is related to improvement of cognition and motor symptoms. In contrast, other nutrients may be involved with the etiology of neurodegeneration or exacerbate disease progression. This review summarizes the studies that have addressed these issues and describes in detail the nutrients and their putative mechanisms of action in PD.

2 February 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JSJose A Santiago
Jose A Santiago
JPJudith Potashkin
Judith Potashkin
Significance: Development of therapeutic strategies for Parkinson’s disease (PD) is hampered by the lack of reliable biomarkers to identify patients at early stages of the disease and track the therapeutic effect of potential drugs and neuroprotective agents. Readily accessible biomarkers capable of providing information about disease status are expected to accelerate this progress. We identified hepatocyte nuclear factor ( HNF4A ) and polypyrimidine tract binding protein 1 ( PTBP1 ) mRNAs as promising blood biomarkers for identifying early stage PD patients with high diagnostic accuracy. Furthermore, HNF4A was identified as a potential biomarker to monitor disease severity. Longitudinal analysis demonstrated that HNF4A and PTBP1 are longitudinally dynamic biomarkers that provide insights into the molecular mechanisms underlying the altered insulin signaling in PD patients and may enable novel therapeutic strategies.

4 December 2017 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
JSJose A Santiago
Jose A Santiago
VBVirginie Bottero
Virginie Bottero
JPJudith Potashkin
Judith Potashkin
A wide spectrum of comorbidities has been associated with Parkinson’s disease (PD), a progressive neurodegenerative disease that affects more than seven million people worldwide. Emerging evidence indicates that chronic diseases including diabetes, depression, anemia and cancer may be implicated in the pathogenesis and progression of PD. Recent epidemiological studies suggest that some of these comorbidities may increase the risk of PD and precede the onset of motor symptoms. Further, drugs to treat diabetes and cancer have elicited neuroprotective effects in PD models. Nonetheless, the mechanisms underlying the occurrence of these comorbidities remain elusive. Herein, we discuss the biological and clinical implications of comorbidities in the pathogenesis, progression, and clinical management, with an emphasis on personalized medicine applications for PD.

1 December 2014 in Neurobiology of Disease
Verified
Journal Article
Closed access
JSJose A Santiago
Jose A Santiago
JPJudith Potashkin
Judith Potashkin